Heron Therapeutics, Inc.
HRTX
$0.84
-$0.03-3.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.36% | 12.60% | 9.78% | 12.43% | 13.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.36% | 12.60% | 9.78% | 12.43% | 13.57% |
| Cost of Revenue | 4.63% | -32.59% | -47.92% | -56.41% | -59.59% |
| Gross Profit | 8.42% | 43.20% | 69.20% | 147.94% | 287.16% |
| SG&A Expenses | 3.17% | 11.87% | 1.70% | -9.31% | -16.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.05% | 5.10% | -10.11% | -22.74% | -29.19% |
| Operating Income | 77.98% | 119.19% | 104.28% | 94.48% | 87.61% |
| Income Before Tax | -48.71% | 51.45% | 98.07% | 90.38% | 87.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.71% | 51.45% | 98.07% | 90.38% | 87.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.71% | 51.45% | 98.07% | 90.38% | 87.72% |
| EBIT | 77.98% | 119.19% | 104.28% | 94.48% | 87.61% |
| EBITDA | 97.52% | 169.45% | 113.67% | 98.03% | 89.97% |
| EPS Basic | -30.68% | 57.91% | 98.12% | 91.67% | 89.72% |
| Normalized Basic EPS | 37.63% | 102.74% | 103.04% | 92.16% | 89.73% |
| EPS Diluted | -43.78% | 51.53% | 94.51% | 90.50% | 89.72% |
| Normalized Diluted EPS | 32.85% | 97.01% | 101.25% | 91.42% | 89.73% |
| Average Basic Shares Outstanding | 9.25% | 3.52% | 1.96% | 7.50% | 13.47% |
| Average Diluted Shares Outstanding | 16.38% | 10.65% | 9.18% | 15.13% | 13.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |